Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) FCF Margin (2016 - 2025)

Historic FCF Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to 56.5%.

  • Vanda Pharmaceuticals' FCF Margin fell 255600.0% to 56.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 39.11%, marking a year-over-year decrease of 295800.0%. This contributed to the annual value of 8.17% for FY2024, which is 146200.0% down from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' FCF Margin stood at 56.5%, which was down 255600.0% from 29.57% recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year FCF Margin high stood at 50.8% for Q1 2023, and its period low was 67.11% during Q1 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median FCF Margin value was 6.6% (recorded in 2022), while the average stood at 1.84%.
  • In the last 5 years, Vanda Pharmaceuticals' FCF Margin surged by 442100bps in 2023 and then tumbled by -830400bps in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' FCF Margin stood at 38.92% in 2021, then plummeted by -64bps to 14.19% in 2022, then crashed by -162bps to 8.8% in 2023, then surged by 57bps to 3.82% in 2024, then crashed by -1380bps to 56.5% in 2025.
  • Its FCF Margin stands at 56.5% for Q3 2025, versus 29.57% for Q2 2025 and 67.11% for Q1 2025.